This research study is a Phase II clinical trial. Phase II clinical trials test the
effectiveness of an investigational drug to learn whether the drug works in treating a
specific cancer. "Investigational" means that the drug is still being studied and that
research doctors are trying to find out more about it-such as the safest dose to use, the
side effects it may cause, and if the drug is effective for treating different types of
cancer. It also means that the FDA has not approved the drug for this type of cancer, or for
any use outside of research studies.
When cancer spreads from the primary tumor, one of the most commons sites it spreads to is
bone. When cancer spreads to bone there can be significant symptoms such as pain.
Cabozantinib works by blocking signaling that leads to cancer growth as well as blocking the
growth of new blood vessels (angiogenesis) that help to feed a tumor. Cabozantinib has been
studied or is being studied in research studies as a possible treatment for various types of
cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer and kidney
cancer.
Previous clinical research studies indicate that cabozantinib may also have activity against
cancer once it has spread to the bones.
The purpose of this study is to find out if cabozantinib is effective in treating cancer that
has spread to the bone.